Loading...
Sexual health and desire
Changes in desire or performance are common, and they are often a signal worth reading rather than something to put up with. These guides cover how hormones, stress, blood flow and relationships shape sexual health for men and women.
Many of the underlying causes show up in a blood panel. Start there, then talk it through with a physician.
38 guides in this topic
Start here
For better sex, and feeling sure of yourself. It starts with your labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.
All sexual health guides (38)
- Bremelanotide is FDA-approved for women: what Vyleesi actually treats
Bremelanotide (Vyleesi) is FDA-approved for premenopausal women with HSDD. The branded form is FDA-approved; compounded PT-141 is not. What the label actually covers, in plain English.
- Erectile dysfunction as a vascular health signal
Erectile dysfunction often shows up years before a cardiovascular event. Why ED is a vascular signal worth taking seriously. Educational only.
- Erectile dysfunction as a vascular-health signal
ED frequently precedes cardiovascular events by two to five years. Endothelial dysfunction is the shared mechanism. Here's what the published research says about ED as a screening opportunity.
- How PDE5 inhibitors boost nitric oxide and blood flow
How PDE5 inhibitors like sildenafil and tadalafil (FDA-approved prescription drugs, not compounded peptides) block an enzyme to keep blood vessels relaxed.
- How PT-141 signals desire through melanocortin receptors
How does PT-141 work? Unlike PDE5 inhibitors, bremelanotide acts in the brain, not the bloodstream. A plain-English walk through melanocortin receptor signaling.
- HSDD explained: female sexual arousal and the brain-body link
HSDD explained — what hypoactive sexual desire disorder is, how the brain-body desire pathway works, and where peptides like bremelanotide fit in clinically.
- Intimacy and stress: how cortisol suppresses desire
Chronic stress raises cortisol, which suppresses sex hormones and desire in both men and women. Here's the mechanism and what the research shows.
- Intimacy, cortisol, and libido: the stress connection
Chronic stress reshapes hormones, sleep, and attention — three of the strongest inputs to libido. Here is what the research links and where peptides fit.
- Low libido in men: what to investigate before reaching for a pill
Low libido in men is rarely just a libido problem. The plain-English checklist a physician runs through before testosterone, peptides, or anything else.
- Low libido in women: how hormones, stress, and peptides intersect
Low libido in women is rarely a single-cause problem. Hormones, stress biology, relationship factors, and medications all play a role. A plain-English map of how peptides fit in.
- Melanotan II vs PT-141: why the FDA approval difference matters
Melanotan II and PT-141 came from the same molecule family — but only one is FDA-approved. Here is what the regulatory split means for patients.
- Melanotan II: what the literature says about risks
Melanotan II is not FDA-approved and not available from 503A compounding pharmacies. Here is what the published case literature says about documented adverse events.
- Oxytocin beyond bonding: stress, intimacy, and the research
Oxytocin is more than the bonding hormone. What the published research says about its role in stress, trust, and intimacy — and where the data gets thin.
- Oxytocin beyond the stereotype: a peptide primer
Oxytocin is more than the 'love hormone' label suggests. Here's the neuroscience — pituitary origin, social bonding studies, and what the intranasal research actually shows.
- Oxytocin research: intimacy, bonding, and sexual health in the literature
Oxytocin research goes well beyond labor and breastfeeding. Trials explore bonding, trust, and sexual function. Here is what the published literature shows.
- Oxytocin vs PT-141: two different paths to intimacy biology
Oxytocin vs PT-141 — how a bonding hormone differs from a melanocortin desire signal. Bremelanotide is FDA-approved as Vyleesi; the compounded form is not.
- PDE5 inhibitor side effects and contraindications
PDE5 inhibitor side effects in plain English — headache, flushing, vision changes, blood pressure drops, and the nitrate interaction every prescriber screens for.
- PT-141 (bremelanotide): how melanocortin signaling affects desire
PT-141 (bremelanotide) is the active ingredient in Vyleesi (FDA-approved for HSDD); compounded versions are not FDA-approved. How the melanocortin pathway works.
- PT-141 dosing and timing: a clinical overview
PT-141 dosing and timing explained: onset, peak, nausea window, and dose limits. Bremelanotide is FDA-approved as Vyleesi; compounded PT-141 for men is not FDA-approved.
- PT-141 FAQ: the sexual health peptide questions answered
PT-141 questions answered in plain English: timing, dose, who it works for, side effects, women vs men, and how it differs from ED pills like sildenafil.
- PT-141 for women: the brain-based path to desire
PT-141 (bremelanotide) acts in the brain — not in the bloodstream — and the FDA-approved version is indicated for premenopausal HSDD. Here is the plain-English breakdown.
- PT-141 for women: what the bremelanotide research shows for female desire
PT-141 (bremelanotide) is the only FDA-approved injectable for low sexual desire in premenopausal women. Here is what the research actually shows, in plain English.
- PT-141 research: bremelanotide in the published literature
PT-141 (bremelanotide) is a melanocortin receptor agonist with FDA approval for one specific indication in women. Here is what the PT-141 research literature actually shows.
- PT-141 side effects: what the literature reports and how nausea is managed
Vyleesi (bremelanotide / PT-141) is FDA-approved for one use; the compounded version is not FDA-approved. Here is what the side effect literature shows.
- PT-141 side effects: what to expect and how nausea is managed
PT-141 side effects: in trials, about 4 in 10 women had nausea, 1 in 5 had flushing, and blood pressure rose briefly. See how long the nausea usually lasts.
- PT-141 vs melanotan-2: what makes bremelanotide different
PT-141 vs melanotan-2 in plain English — same family, different design, different approval status. Why bremelanotide is FDA-approved and melanotan-2 is not.
- PT-141 vs sildenafil: two different mechanisms for two different problems
PT-141 vs sildenafil in plain English: a brain peptide that signals desire vs a vascular drug that supports erection. Two mechanisms, two different problems, side by side.
- Spontaneous vs responsive desire: two normal patterns
Spontaneous desire comes on its own; responsive desire appears after touch or closeness begins. Both are normal. See what research found and when to get help.
- The melanocortin system: why PT-141 works at the brain level
PT-141 acts on the brain's melanocortin system, not on blood flow. Here is how the MC4R pathway connects to sexual desire — and what makes it unlike Viagra.
- The vascular theory of ED: why blood flow comes before anything else
Erectile dysfunction is most commonly a vascular issue — not a psychological one. Understanding the blood flow mechanism changes how physicians and patients approach it.
- What PDE5 inhibitors are and how they work
PDE5 inhibitors explained: what they are, how they work at the molecular level, and how they fit into the broader landscape of men's sexual health options.
- Who asks about female libido and what they want to know
Who searches for female libido treatments, why low desire is underdiagnosed, and what the research says about causes and clinical options for women over 40.
- Who asks about melanotan-2 and what draws them to it
Melanotan-2 is an unapproved peptide linked to tanning and libido claims; here's who asks about it, why, and the safety facts (FDA, MHRA, TGA).
- Who asks about prescription oxytocin and why
Oxytocin is a hormone the body makes, studied for bonding and intimacy. Here's who asks about prescription oxytocin and what the research shows.
- Who asks about PT-141 and the questions behind the search
People searching for PT-141 are usually asking about low libido that has not responded to other approaches. Here is who asks and what they want to know.
- Who should be screened for vascular causes of ED
ED is often the first symptom of artery disease, sometimes years before a heart attack. Here is the group of men whose ED deserves a real cardiovascular workup.
- Why ED is a vascular problem first
Erectile dysfunction is most often a blood flow issue before anything else. Here is what the cardiology research links it to and why screening matters.
- Why men's sexual health is a cardiovascular screening opportunity
Erectile dysfunction often appears years before a cardiac event. Research shows it's a vascular signal — here's what the data says and what to do with it.